glp 1 marketing GLP-1 Receptor Agonist Market Size GLP-1 Obesity Deal Trends Report

"Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity"

FDA ramps up its pushback against compounded GLP-1s In a move that will delight Novo Nordisk and Eli Lilly, the FDA has sent warning letters to 30 telehealth companies, accusing them of illegally marketing compounded GLP-1 agonist formulations

Seek immediate medical attention if you experience severe, persistent abdominal pain, especially if it radiates to your back, as this could indicate pancreatitisa rare but serious adverse effect associated with GLP-1 receptor agonists

In March of 2024, the Collaborative of Eating Disorders Organizations, an alliance of groups that treat eating disorders, called for providers to screen patients for eating disorders before prescribing weight loss drugs, arguing that the medications are unsafe for people in recovery